Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Accumulated Expenses: 2019-2024

Historic Other Accumulated Expenses for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $2.3 million.

  • Nurix Therapeutics' Other Accumulated Expenses rose 161.33% to $1.7 million in Q3 2025 from the same period last year, while for Aug 2025 it was $1.7 million, marking a year-over-year increase of 161.33%. This contributed to the annual value of $2.3 million for FY2024, which is 202.93% up from last year.
  • Per Nurix Therapeutics' latest filing, its Other Accumulated Expenses stood at $2.3 million for FY2024, which was up 202.93% from $751,000 recorded in FY2023.
  • Nurix Therapeutics' 5-year Other Accumulated Expenses high stood at $2.3 million for FY2024, and its period low was $659,000 during FY2021.
  • In the last 3 years, Nurix Therapeutics' Other Accumulated Expenses had a median value of $1.5 million in 2022 and averaged $1.5 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 50.03% in 2023, then soared by 202.93% in 2024.
  • Nurix Therapeutics' Other Accumulated Expenses (Yearly) stood at $700,000 in 2020, then fell by 5.86% to $659,000 in 2021, then skyrocketed by 128.07% to $1.5 million in 2022, then slumped by 50.03% to $751,000 in 2023, then surged by 202.93% to $2.3 million in 2024.